Efficacy of telavancin against MRSA

Link: Efficacy of telavancin in a murine model of pneumonia induced by methicillin-susceptible Staphylococcus aureus -- Hegde et al., 10.1093/jac/dkm417 -- Journal of Antimicrobial Chemotherapy.

Results: At 48 h post-inoculation in the low and high pre-treatment titre groups, respectively, telavancin produced greater reductions (from pre-treatment values) in bacterial burden (–4.3 and –3.2 log10 cfu/g) than nafcillin (–1.3 and –1.8 log10 cfu/g), vancomycin (–2.9 and –2.2 log10 cfu/g) and linezolid (–0.4 and  0.3 log10 cfu/g). Conclusions: These findings support the potential clinical utility of telavancin in the treatment of MSSA pneumonia.